Trontinemab

← Pipeline

Trontinemab

Roche · Alzheimer's disease
Mid-stage active recruiting CT.gov grounded

Roche's differentiated amyloid program designed for stronger CNS delivery dynamics.

Open Alzheimer's disease hub Filter main pipeline

Program overview

Mechanism
anti-amyloid antibody with brain shuttle design
Modality
engineered antibody
Phase
Mid-stage
Status
active
Recruitment
recruiting
Confidence
medium
Watch priority
2
Last verified
20 Apr 2026

Sponsor and trial identifiers

Sponsor
Roche
Trial IDs
NCT07170150, NCT07169578
ClinicalTrials.gov exact matches: NCT07170150, NCT07169578

Regions and recruitment

Active in 18 regions
United States Argentina Australia Brazil Canada Denmark France Germany Italy Japan Netherlands Poland South Korea Spain Switzerland United Kingdom China Taiwan

Indication tags

Alzheimer's

Milestones and catalysts

Last milestone
Roche's brain-shuttle framing makes this program strategically interesting beyond headline phase labels.
Next expected catalyst
Mid-stage data maturity and competitive positioning updates.

Related pages

Disease hub Alzheimer's disease hub Disease-specific views with programs, mechanisms, and related context.
Research Research agenda Research notes and background around Alzheimer's disease.
Key Targets Key targets The mechanisms and intervention levers behind these programs.
Discover Discover Explainers and visual introductions to the science behind neurodegeneration.
Join Get involved Contribute research, writing, design, engineering, or review.

Related programs

Each card explains why it is here so you can read the overlap at a glance.

Priority 1
Approved / Late-stage active active, not recruiting

Late-stage anti-amyloid program with high strategic importance for the Alzheimer's treatment landscape.

Shown because it shares same disease bench and shared biology: alzheimer's with Trontinemab.
Mechanism
anti-amyloid antibody
Modality
monoclonal antibody
Next catalyst
Further rollout, label evolution, and follow-up data.
Last verified
20 Apr 2026

Lecanemab

Eisai / Biogen · Alzheimer's disease
Priority 1
Approved / Late-stage active active, not recruiting

Anti-amyloid antibody program targeting plaque clearance in early Alzheimer's disease.

Shown because it shares same disease bench and shared biology: alzheimer's with Trontinemab.
Mechanism
anti-amyloid antibody
Modality
monoclonal antibody
Next catalyst
Additional post-approval data and uptake signals.
Last verified
20 Apr 2026
Priority 2
Late-stage active active, not recruiting

A precision-style Alzheimer's program built around APOE4 biology rather than a broad undifferentiated patient pool.

Shown because it shares same disease bench and shared biology: alzheimer's with Trontinemab.
Mechanism
anti-amyloid oligomer modulation
Modality
small molecule
Next catalyst
Long-term extension updates and any signal on APOE4-enriched positioning.
Last verified
20 Apr 2026
Priority 2
Mid / Late-stage active active, not recruiting

Follow-on anti-amyloid program that could matter for the next wave of Alzheimer's competition.

Shown because it shares same disease bench and shared biology: alzheimer's with Trontinemab.
Mechanism
anti-amyloid antibody
Modality
monoclonal antibody
Next catalyst
Recruitment updates and larger efficacy or safety read-throughs.
Last verified
20 Apr 2026

Source links

ClinicalTrials.gov NCT07170150 ClinicalTrials.gov NCT07169578 ClinicalTrials.gov search Roche pipeline
Scroll to Top